Guardant Health (GH) Stock News

Guardant Health (GH) presented groundbreaking results from the largest molecular residual disease study in colon cancer at ASCO 2025. The study, involving over 2,000 stage III colon cancer patients with 6.1 years median follow-up, demonstrated the effectiveness of their Guardant Reveal blood test in predicting cancer recurrence risk and survival outcomes. The test detected that 62.6% of patients with post-surgical circulating tumor DNA (ctDNA) experienced cancer recurrence within 3 years despite chemotherapy, compared to only 15.4% in patients with undetectable ctDNA. This breakthrough enables better identification of high-risk patients who may need more aggressive treatment, as approximately 30% of stage III colon cancer patients typically relapse after surgery despite standard chemotherapy.

Guardant Health (NASDAQ: GH) has unveiled significant enhancements to its Guardant360® Liquid test, introducing nearly a dozen new smart liquid biopsy applications. The expanded capabilities, powered by the Guardant Infinity™ platform and AI learning engine, enable comprehensive tumor analysis through a simple blood test. Key innovations include: confirming absence of actionable mutations in lung and colorectal cancers, identifying cancer origin for unknown primary sites, classifying breast and lung cancer subtypes through methylation signatures, utilizing pharmacogenomics for therapy safety, detecting HPV and EBV viruses, determining HRD status, and performing HLA genotyping. The test delivers results within seven days and provides molecular profiling information traditionally obtained through tissue-based immunohistochemistry, representing a significant advancement in non-invasive cancer diagnostics.

Guardant Health (GH) will present data from over 19 studies at the 2025 ASCO Annual Meeting, showcasing their liquid biopsy tests' role in cancer care. Key highlights include: 1) A plenary session featuring the Phase 3 SERENA-6 trial demonstrating Guardant360 CDx test's ability to detect ESR1 mutations in breast cancer patients, 2) An oral session presenting the largest study of Guardant Reveal for molecular residual disease detection in colon cancer, involving over 2,000 patients with 6.1 years median follow-up, 3) Validation of an algorithm predicting absence of actionable mutations in colorectal and lung cancers, and 4) Application of epigenomic-based classifier for identifying tumor types in cancer of unknown primary origin. The presentations span various applications including cancer screening, therapy selection, and recurrence monitoring across multiple solid tumor types.

Guardant Health (Nasdaq: GH) has expanded its testing portfolio by introducing a comprehensive immunohistochemistry (IHC) testing suite for solid tumors. The new tests detect specific proteins (biomarkers) in tissue samples to help oncologists identify tumor characteristics and match patients with targeted therapies. The IHC suite covers key biomarkers including HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.

This addition complements Guardant's existing Guardant360 Tissue multiomic tumor profiling test. Notably, the suite includes testing for c-MET, which is crucial for identifying patients eligible for the newly FDA-approved Emrelis™ treatment for c-MET-expressing non-squamous non-small cell lung cancer (NSCLC).

Guardant Health (NASDAQ: GH) has launched the Guardant Hereditary Cancer test, a blood-based germline panel test that identifies genetic variants linked to cancer risk. The test analyzes 82 genes associated with increased risk for more than 12 tumor types, including breast, colorectal, prostate, endometrial, and renal cancers. This germline testing helps guide treatment decisions and enables healthcare providers to assess patient risk for secondary cancers. The test requires a simple blood draw, can be ordered standalone or added to Guardant360 liquid biopsy tests, and delivers results in 2-3 weeks. The launch expands Guardant's precision oncology portfolio and supports healthcare providers across the cancer care continuum.

Guardant Health (Nasdaq: GH), a precision oncology company, has announced its participation in three major upcoming investor conferences in 2025:

• BofA Securities Healthcare Conference in Las Vegas - May 14th at 3:40 PM PT
• Jefferies Global Healthcare Conference in New York - June 4th at 2:35 PM ET
• Goldman Sachs Global Healthcare Conference in Miami Beach - June 9th at 10:00 AM ET

The company will participate in fireside chat sessions at each event. Live and archived webcasts will be available on Guardant Health's investor relations website.

TIME has named Guardant Health (NASDAQ: GH) co-CEOs Helmy Eltoukhy and AmirAli Talasaz to its prestigious 2025 TIME100 Health list, recognizing the most influential people in global health. The recognition highlights Guardant's achievements in precision oncology, particularly their Shield blood test for colorectal cancer, which is FDA-approved for primary non-invasive screening in average-risk individuals aged 45 and older. The company recently presented promising data for their multi-cancer detection blood test at the AACR annual meeting. Guardant's technology aims to replace invasive biopsies, enable faster treatment decisions, and advance early cancer detection capabilities.

Guardant Health (NASDAQ: GH) announced the approval of equity grants to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants include 157,466 restricted stock units (RSUs) awarded to 139 employees and stock options to purchase 19,295 shares granted to 2 employees. The stock options have an exercise price of $46.85 per share. RSUs vest annually over 3 years, while stock options vest with one-third after the first year and monthly thereafter over 24 months. These grants were approved on April 22, 2025, with a grant date of May 2, 2025, and were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Guardant Health reported strong Q1 2025 financial results, with total revenue reaching $203.5 million, marking a 21% year-over-year growth. The company raised its 2025 revenue guidance to $880-890 million, projecting 19-20% growth.

Key performance highlights include:

• Oncology revenue grew 20% to $150.6 million, with test volume up 25%
• Screening revenue reached $5.7 million from 9,000 Shield tests
• Biopharma & Data revenue increased 21% to $45.4 million

Notable achievements include receiving ADLT status from CMS for Shield, increasing Medicare pricing to $1,495, and securing first Shield payor coverage from VA Community Care Network. The company launched an upgraded Guardant360 Tissue test and announced a collaboration with Pfizer. Despite progress, net loss was $95.2 million, improving from $115.0 million in the previous year.